Pharvaris N.V. (PHVS) stock
Close on Nov 11, 2026Market cap $2.23BP/E –Yield –
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026
Valuation
- Market cap
- €2.00B
- P/E ratio
- –
- Price to sales
- –
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- -6.87%
Fundamentals
- EPS, diluted
- -2.97 EUR
- Free cash flow
- -€137.24M
- Diluted shares
- 68M
Trading
- Previous close
- $33.99
- Open
- $34.01
- Day's range
- $33.81 – $34.73
- Volume
- 421,746
- Average volume (20 days)
- 671,003
- Beta (5 years)
- -0.54
- RSI (14 days)
- 57.2
- Volatility (1 year)
- 54.0%
- Relative volume
- 0.59×
- WACC
- 7.4%
Market cap history
Month-end market cap since 2021, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | PHVS | S&P 500 | Difference | PHVS per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | +9.9% | -2.4% | +12.3 pts | ||
| 3 months | -0.7% | -1.2% | +0.5 pts | ||
| Year to date | +23.2% | +12.3% | +10.9 pts | ||
| 1 year | +41.7% | +12.4% | +29.3 pts | ||
| 3 years | +94.2% | +78.8% | +15.4 pts | +24.8% | +21.4% |
| 5 years | +113.6% | +75.2% | +38.5 pts | +16.4% | +11.9% |
Nine years at a glance
Fiscal years 2017 to 2025, EUR
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Pharvaris filed with the SEC as exhibits to Form 8-K or 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
About Pharvaris
Pharmaceutical Preparations
Pharvaris N.V. is a clinical-stage biopharmaceutical enterprise focused on discovering and advancing novel oral therapies. The company is developing treatments targeting bradykinin-mediated conditions, specifically focusing on hereditary angioedema. Its main developmental product candidates are oral formulations of deucrictibant, which include immediate-release capsules designed for acute attack management and extended-release tablets intended for preventative treatment. Its target customer base consists of individuals suffering from rare angioedema disorders and related conditions.
Company profile, executives and historyPharvaris stock: common questions
What is Pharvaris's stock price?
PHVS closed at $34.18 on Nov 11, 2026, up 0.56% on the day.
What is Pharvaris's market cap?
Pharvaris was worth $2.23B at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
What is PHVS's P/E ratio?
Pharvaris lost money over fiscal 2025 (diluted EPS -2.97 EUR), so it has no meaningful P/E ratio.
Does Pharvaris pay a dividend?
No. Pharvaris has not paid a cash dividend over the last twelve months.
How has PHVS stock performed over the past year?
Including dividends, PHVS returned +41.7% over the past year, against +12.4% for the S&P 500.
Who are Pharvaris's competitors?
Companies most similar to Pharvaris by business, industry and size include PHAR, OCS, NAMS, PRQR, INSM.
See a number that looks wrong?